Raymond James Downgrades Tesaro (TSRO) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
TESARO Announces Third-Quarter 2016 Operating Results
November 3, 2016 4:07 PM EDTNiraparib rolling NDA submission to FDA complete, MAA accepted for review by EMAPre-launch planning ongoing to support four potential product launches in 2017 across U.S. and EuropePositive Phase 3 NOVA trial results presented during Presidential Symposium at ESMO 2016 and simultaneously published in New England Journal of MedicineCash and cash equivalents totaled approximately $647 million as of September 30, 2016
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today reported operating results... More
